Skip to content

The Assistance Fund – ASMD Financial Assistance Program

The Assistance Fund’s ASMD financial assistance program provides financial assistance for the following:

  • Prescription drug assistance (copays, deductibles, and coinsurance) on all FDA-approved treatment for ASMD
  • Health insurance premiums
  • Therapy administration costs
  • Disease management (such as prescribing-physician copayments)
  • Treatment-related travel costs
  • Genetic testing

The Assistance Fund (TAF) helps patients and families facing high medical out-of-pocket costs by providing financial assistance for co-payments, coinsurance, deductibles, and other health-related expenses. Since its founding in 2009, TAF has helped more than 160,000 children and adults in all 50 states, Washington, DC, and Puerto Rico.

Among TAF’s 80 disease programs is the Acid Sphingomyelinase Deficiency (ASMD) Financial Assistance Program. The Acid Sphingomyelinase Deficiency Financial Assistance Program provides financial assistance for out-of-pocket costs associated with all FDA-approved treatment for ASMD, including prescription drugs (copays, deductibles, and coinsurance), health insurance premiums, therapy administration costs, disease management (such as prescribing physician copayments), treatment-related travel costs, and genetic testing.

To be eligible for assistance, patients must be U.S. citizens or permanent residents, meet certain income requirements, have a diagnosis of the disease named in the disease program, have government or private health insurance, and a prescription for an FDA-approved treatment for ASMD. Once a patient is enrolled in a disease program, their coverage lasts the entire calendar year and there is no cap on the amount of assistance in that calendar year.

To learn more, or to apply today, visit or call (855) 233-0505.

ASMD Financial Assistance Program – One Pager
The Assistance Fund Press Release 01/16/2023

Supporting one another. Supporting our community.